https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-q2-2026-results BiopharmaWatch en 2026-08-11T20:54:17.000Z Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/APLM/apollomics-announces-10-million-private-placement BiopharmaWatch en 2026-08-11T20:36:18.000Z Apollomics Announces $10 Million Private Placement Transaction https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-q2-2026-results-business-update BiopharmaWatch en 2026-08-11T20:10:27.000Z Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update https://www.biopharmawatch.com/news/TRLV/trulieve-redomicile-bc-to-delaware BiopharmaWatch en 2026-08-11T20:10:00.000Z Trulieve Completes Redomicile from British Columbia to Delaware https://www.biopharmawatch.com/news/VNRX/volitionrx-schedules-q2-2026-earnings-call BiopharmaWatch en 2026-08-11T20:10:00.000Z VolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update https://www.biopharmawatch.com/news/ABSI/absci-reports-business-updates-q2-2026-results BiopharmaWatch en 2026-08-11T20:05:20.000Z Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-corporate-update-q2-2026 BiopharmaWatch en 2026-08-11T20:05:17.000Z Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/MDAI/spectral-ai-2026-q2-financial-results BiopharmaWatch en 2026-08-11T20:05:16.000Z Spectral AI Announces 2026 Second Quarter Financial Results https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-08-11T20:05:16.000Z Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-08-11T20:05:00.000Z Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-11T20:05:00.000Z LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights https://www.biopharmawatch.com/news/MGNX/macrogenics-gilead-milestone-license-bispecific-program BiopharmaWatch en 2026-08-11T20:05:00.000Z MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program https://www.biopharmawatch.com/news/DRMA/dermata-therapeutics-corporate-update-q2-2026 BiopharmaWatch en 2026-08-11T20:05:00.000Z Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026 https://www.biopharmawatch.com/news/NPCE/neuropace-q2-2026-financial-results BiopharmaWatch en 2026-08-11T20:05:00.000Z NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance https://www.biopharmawatch.com/news/ELMD/electromed-q4-fiscal-2026-financial-results BiopharmaWatch en 2026-08-11T20:05:00.000Z Electromed, Inc. to Report Q4 Fiscal 2026 Financial Results on August 25, 2026 https://www.biopharmawatch.com/news/SVRA/savara-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-11T20:05:00.000Z Savara Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/INVA/innoviva-therapies-prix-galien-finalists-2026 BiopharmaWatch en 2026-08-11T20:05:00.000Z Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-pipeline-progress-q2-2026 BiopharmaWatch en 2026-08-11T20:02:27.000Z Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/IMNM/immunome-q2-2026-financial-results-update BiopharmaWatch en 2026-08-11T20:02:00.000Z Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-11T20:01:32.000Z Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-q2-2026-update BiopharmaWatch en 2026-08-11T20:01:30.000Z Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/BLTE/belite-bio-fda-acceptance-tinlarebant-stargardt-disease BiopharmaWatch en 2026-08-11T20:01:28.000Z Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1 https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-11T20:01:00.000Z Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity https://www.biopharmawatch.com/news/ERAS/erasca-reports-q2-2026-business-updates BiopharmaWatch en 2026-08-11T20:01:00.000Z Erasca Reports Second Quarter 2026 Business Updates and Financial Results https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-q2-2026-results-update BiopharmaWatch en 2026-08-11T20:00:28.000Z Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/TXMD/therapeuticsmd-q2-2026-financial-results BiopharmaWatch en 2026-08-11T20:00:00.000Z TherapeuticsMD Announces Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-11T20:00:00.000Z AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights https://www.biopharmawatch.com/news/ACB/aurora-cannabis-responds-curaleaf-takeover-bid BiopharmaWatch en 2026-08-11T19:22:00.000Z AURORA CANNABIS INC. RESPONDS TO PRESS RELEASE OF CURALEAF HOLDINGS, INC. REGARDING INTENTION TO LAUNCH UNSOLICITED TAKE-OVER BID https://www.biopharmawatch.com/news/GMAB/genmab-capital-increase-employee-warrant-exercise BiopharmaWatch en 2026-08-11T17:54:09.000Z Capital Increase in Genmab as a Result of Employee Warrant Exercise https://www.biopharmawatch.com/news/CRDL/inflammation-heart-why-field-asking-different-question BiopharmaWatch en 2026-08-11T14:19:51.000Z Inflammation and the Heart: Why the Field Is Asking a Different Question https://www.biopharmawatch.com/news/VOR/vor-bio-reports-q2-2026-results BiopharmaWatch en 2026-08-11T13:30:10.000Z Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/IGC/igc-pharma-strengthens-regulatory-readiness-calma-trial BiopharmaWatch en 2026-08-11T13:17:13.000Z IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer’s Trial Approaches Enrollment Closure and Q4 Topline Readout https://www.biopharmawatch.com/news/AVXL/anavex-highlights-board-actions-long-term-value BiopharmaWatch en 2026-08-11T12:42:53.000Z Anavex Life Sciences Highlights Highly Qualified Board and Decisive Actions to Create Long-Term Value for Stockholders https://www.biopharmawatch.com/news/RNXT/renovorx-phase-iii-tiger-pac-trial-enrollment-complete BiopharmaWatch en 2026-08-11T12:30:00.000Z RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-q2-2026-financial-results BiopharmaWatch en 2026-08-11T12:30:00.000Z Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/ADGM/adagio-medical-reports-q2-2026-results BiopharmaWatch en 2026-08-11T12:30:00.000Z Adagio Medical Reports Second Quarter 2026 Results https://www.biopharmawatch.com/news/WGS/genedx-online-offering-exome-testing-children BiopharmaWatch en 2026-08-11T12:30:00.000Z GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy https://www.biopharmawatch.com/news/FBLG/fibrobiologics-patent-fibroblasts-islet-transplantation BiopharmaWatch en 2026-08-11T12:30:00.000Z FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets https://www.biopharmawatch.com/news/ACB/curaleaf-takeover-bid-aurora-cannabis BiopharmaWatch en 2026-08-11T12:25:00.000Z Curaleaf Announces Intention to Launch Take-Over Bid for Aurora Cannabis to Solidify its Position as the Global Cannabis Industry Leader https://www.biopharmawatch.com/news/RKTO/rocket-one-seagate-partner-program-ai-infrastructure BiopharmaWatch en 2026-08-11T12:12:00.000Z Rocket One Accepted into Seagate Partner Program, Expanding AI Infrastructure and Enterprise Data Storage Ecosystem https://www.biopharmawatch.com/news/BFLY/butterfly-network-congratulates-dr-erica-schwartz-cdc-director BiopharmaWatch en 2026-08-11T12:05:00.000Z Butterfly Network Congratulates Dr. Erica Schwartz on Confirmation as CDC Director https://www.biopharmawatch.com/news/KLRS/kalaris-q2-2026-financial-results-business-updates BiopharmaWatch en 2026-08-11T12:00:35.000Z Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/TARA/protara-therapeutics-q2-2026-results-update BiopharmaWatch en 2026-08-11T12:00:00.000Z Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-imcivree-authorization-uk BiopharmaWatch en 2026-08-11T12:00:00.000Z Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment https://www.biopharmawatch.com/news/IMNN/imunon-reports-q2-2026-results-business-update BiopharmaWatch en 2026-08-11T12:00:00.000Z IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/ESLA/estrella-immunopharma-activates-fourth-clinical-site BiopharmaWatch en 2026-08-11T12:00:00.000Z Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma https://www.biopharmawatch.com/news/ARDT/oklahoma-heart-institute-national-cardiovascular-trials BiopharmaWatch en 2026-08-11T12:00:00.000Z Oklahoma Heart Institute Brings New National Cardiovascular Trials and Technologies to Patients Across the Region https://www.biopharmawatch.com/news/COYA/coya-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-11T12:00:00.000Z Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update https://www.biopharmawatch.com/news/HSTM/humana-health-horizons-healthstream-home-care-workforce BiopharmaWatch en 2026-08-11T12:00:00.000Z Humana Healthy Horizons in Indiana Collaborates with HealthStream to Expand and Strengthen Home Care Workforce https://www.biopharmawatch.com/news/NVO/novonordisk-launches-awiqli-weekly-basal-insulin BiopharmaWatch en 2026-08-11T12:00:00.000Z Novo Nordisk's Awiqli®, the first once-weekly basal insulin for adults with type 2 diabetes, now available in the US https://www.biopharmawatch.com/news/MREO/sentynl-mereo-alvelestat-agreement-aatd-lung-disease BiopharmaWatch en 2026-08-11T12:00:00.000Z Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD) https://www.biopharmawatch.com/news/EIKN/eikon-therapeutics-teluride-006-dose-selection BiopharmaWatch en 2026-08-11T11:30:36.000Z Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-leadership-transition-growth BiopharmaWatch en 2026-08-11T11:30:28.000Z Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-q2-2026-financial-results BiopharmaWatch en 2026-08-11T11:30:00.000Z Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates https://www.biopharmawatch.com/news/MANE/veradermics-q2-2026-financial-results-clinical-progress BiopharmaWatch en 2026-08-11T11:30:00.000Z Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress https://www.biopharmawatch.com/news/NGNE/neurogene-q2-2026-financial-results-updates BiopharmaWatch en 2026-08-11T11:30:00.000Z Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates https://www.biopharmawatch.com/news/OGN/organon-rems-program-miu-della-launch BiopharmaWatch en 2026-08-11T11:30:00.000Z Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability https://www.biopharmawatch.com/news/ZURA/zura-bio-q2-2026-financial-results BiopharmaWatch en 2026-08-11T11:30:00.000Z Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-08-11T11:30:00.000Z Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/LLY/eli-lilly-veeva-vault-crm-global-implementation BiopharmaWatch en 2026-08-11T11:03:00.000Z Veeva Vault CRM seleccionado por Eli Lilly and Company https://www.biopharmawatch.com/news/LLY/veeva-vault-crm-selected-by-eli-lilly BiopharmaWatch en 2026-08-11T11:03:00.000Z Veeva Vault CRM Selected by Eli Lilly and Company https://www.biopharmawatch.com/news/LLY/eli-lilly-selects-veeva-vault-crm BiopharmaWatch en 2026-08-11T11:03:00.000Z Veeva Vault CRM von Eli Lilly and Company ausgewählt https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-us-notice-allowance-ph-894 BiopharmaWatch en 2026-08-11T11:01:11.000Z Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894 https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-q2-2026-financial-results BiopharmaWatch en 2026-08-11T11:01:00.000Z Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/UPB/upstream-bio-q2-2026-financial-results-progress BiopharmaWatch en 2026-08-11T11:00:44.000Z Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-q2-2026-results-business-highlights BiopharmaWatch en 2026-08-11T11:00:42.000Z C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/COAG/hemab-therapeutics-q2-2026-results-update BiopharmaWatch en 2026-08-11T11:00:42.000Z Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/KLRA/kailera-therapeutics-appoints-nur-nicholson-cto BiopharmaWatch en 2026-08-11T11:00:35.000Z Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-phase-1-study-prt13722 BiopharmaWatch en 2026-08-11T11:00:30.000Z Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-q2-2026-results-business-highlights BiopharmaWatch en 2026-08-11T11:00:29.000Z Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights https://www.biopharmawatch.com/news/CALC/calcimedica-reports-q2-2026-results BiopharmaWatch en 2026-08-11T11:00:00.000Z CalciMedica Reports Second Quarter 2026 Financial Results and Provides Clinical & Corporate Updates https://www.biopharmawatch.com/news/LEGN/legend-biotech-q2-2026-results-highlights BiopharmaWatch en 2026-08-11T11:00:00.000Z Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights https://www.biopharmawatch.com/news/ACIU/fda-fast-track-aciu-aci-7104-parkinsons BiopharmaWatch en 2026-08-11T11:00:00.000Z AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD) https://www.biopharmawatch.com/news/AURA/aura-biosciences-phase-3-trial-enrollment-update BiopharmaWatch en 2026-08-11T11:00:00.000Z Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/BRKR/bruker-collaboration-atinary-technologies BiopharmaWatch en 2026-08-11T11:00:00.000Z Bruker Announces Strategic Collaboration with Atinary Technologies to Advance Self-Driving Laboratories https://www.biopharmawatch.com/news/KARD/kardigan-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-11T11:00:00.000Z Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates https://www.biopharmawatch.com/news/XTNT/xtant-medical-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-11T11:00:00.000Z Xtant Medical Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/CAH/cardinal-health-fiscal-year-2026-results-guidance BiopharmaWatch en 2026-08-11T10:45:00.000Z Cardinal Health Reports Fourth Quarter and Fiscal Year 2026 Results and Provides Fiscal Year 2027 Guidance https://www.biopharmawatch.com/news/DRIO/dariohealth-reports-q2-2026-results BiopharmaWatch en 2026-08-11T10:30:00.000Z DarioHealth Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/IMUX/immunic-reports-q2-2026-results-and-update BiopharmaWatch en 2026-08-11T10:30:00.000Z Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/YDES/yd-bio-launches-new-healthcare-models-taiwan BiopharmaWatch en 2026-08-11T09:22:27.000Z YD Bio 在台灣啟動醫師夥伴計畫，推出兩款時間營養學配方 https://www.biopharmawatch.com/news/YDES/yd-bio-physician-partnership-taiwan-chrono-nutrition BiopharmaWatch en 2026-08-11T09:22:22.000Z YD Bio Launches a Physician-Partnership Initiative in Taiwan with Two Chrono-Nutrition Formulations https://www.biopharmawatch.com/news/RVMD/beone-revolution-medicines-partnership-oncology BiopharmaWatch en 2026-08-10T21:07:00.000Z BeOne Medicines وRevolution Medicines تعلنان عن شراكة للتطوير السريري والتسويق التجاري الإقليمي https://www.biopharmawatch.com/news/KOD/kodiak-sciences-phase-3-alto-trial-ksi-501 BiopharmaWatch en 2026-08-10T20:43:00.000Z Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema https://www.biopharmawatch.com/news/SCYX/scynexis-q2-2026-financial-results-update BiopharmaWatch en 2026-08-10T20:30:00.000Z SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-q2-2026-results BiopharmaWatch en 2026-08-10T20:30:00.000Z DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights https://www.biopharmawatch.com/news/ALC/alcon-second-quarter-2026-growth BiopharmaWatch en 2026-08-10T20:30:00.000Z New Product Launches and Strong Commercial Execution Drive Alcon's Second-Quarter 2026 Growth https://www.biopharmawatch.com/news/EHC/encompass-health-prices-additional-senior-notes-offering BiopharmaWatch en 2026-08-10T20:30:00.000Z Encompass Health prices private offering of additional 5.875% senior notes due 2034 https://www.biopharmawatch.com/news/JNJ/johnson-johnson-morgan-stanley-healthcare-conference-2026 BiopharmaWatch en 2026-08-10T20:27:00.000Z Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/NKTX/nkarta-reports-q2-2026-results-highlights BiopharmaWatch en 2026-08-10T20:24:37.000Z Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights https://www.biopharmawatch.com/news/PALI/palisade-bio-reports-q2-2026-results-phase-2-development BiopharmaWatch en 2026-08-10T20:20:15.000Z Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development https://www.biopharmawatch.com/news/AGMB/agomab-proposed-appointments-board-directors BiopharmaWatch en 2026-08-10T20:07:49.000Z Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors https://www.biopharmawatch.com/news/ALMS/envudeucitinib-long-term-data-plaque-psoriasis-treatment BiopharmaWatch en 2026-08-10T20:05:37.000Z Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies https://www.biopharmawatch.com/news/PROK/prokidney-reports-q2-2026-results BiopharmaWatch en 2026-08-10T20:05:36.000Z ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/MGX/metagenomi-therapeutics-business-updates-q2-2026-results BiopharmaWatch en 2026-08-10T20:05:36.000Z Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ANNX/annexon-appoints-mark-blumenkranz-board-directors BiopharmaWatch en 2026-08-10T20:05:36.000Z Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors https://www.biopharmawatch.com/news/VERA/vera-therapeutics-business-update-q2-2026-results BiopharmaWatch en 2026-08-10T20:05:30.000Z Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/HROW/harrow-announces-q2-2026-financial-results BiopharmaWatch en 2026-08-10T20:05:30.000Z Harrow Announces Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/SANA/sana-biotechnology-q2-2026-results-updates BiopharmaWatch en 2026-08-10T20:05:22.000Z Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates https://www.biopharmawatch.com/news/DMRA/damora-therapeutics-q2-2026-results BiopharmaWatch en 2026-08-10T20:05:00.000Z Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights https://www.biopharmawatch.com/news/QGEN/qiagen-fda-clearance-qiastat-dx-bloodstream-infection-panel BiopharmaWatch en 2026-08-10T20:05:00.000Z QIAGEN Receives U.S. FDA Clearance for First QIAstat-Dx Bloodstream Infection Panel https://www.biopharmawatch.com/news/HIMS/hims-hers-health-q2-2026-financial-results BiopharmaWatch en 2026-08-10T20:05:00.000Z Hims & Hers Health, Inc. Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/PIII/p3-health-partners-q2-2026-results BiopharmaWatch en 2026-08-10T20:05:00.000Z P3 Health Partners Announces Second Quarter 2026 Results https://www.biopharmawatch.com/news/IMUX/immunic-appoints-elena-ridloff-board-directors BiopharmaWatch en 2026-08-10T20:05:00.000Z Immunic Appoints Elena Ridloff to Board of Directors https://www.biopharmawatch.com/news/BHVN/biohaven-reports-business-developments-q2-2026-results BiopharmaWatch en 2026-08-10T20:02:00.000Z Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-q2-2026-results BiopharmaWatch en 2026-08-10T20:01:49.000Z Olema Oncology Reports Second Quarter 2026 Financial and Operating Results https://www.biopharmawatch.com/news/SEPN/septerna-business-progress-q2-2026-results BiopharmaWatch en 2026-08-10T20:01:36.000Z Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ERAS/erasca-inducement-grants-nasdaq-listing-rule-5635c4 BiopharmaWatch en 2026-08-10T20:01:00.000Z Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-financial-results-q3-2026 BiopharmaWatch en 2026-08-10T20:01:00.000Z Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026 https://www.biopharmawatch.com/news/SLN/silence-therapeutics-public-offering-150-million BiopharmaWatch en 2026-08-10T20:01:00.000Z Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-q2-2026-results BiopharmaWatch en 2026-08-10T20:00:00.000Z Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress https://www.biopharmawatch.com/news/ONC/beone-revolution-medicines-collaboration-onc BiopharmaWatch en 2026-08-10T17:03:00.000Z Samenvatting: BeOne Medicines en Revolution Medicines kondigen samenwerking aan voor klinische ontwikkeling en regionale commercialisering https://www.biopharmawatch.com/news/ONC/beone-revolution-collaboration-clinical-development BiopharmaWatch en 2026-08-10T17:02:00.000Z BeOne Medicines und Revolution Medicines kündigen Zusammenarbeit bei klinischer Entwicklung und regionaler Vermarktung an https://www.biopharmawatch.com/news/HELP/helus-pharma-participate-canaccord-growth-conference BiopharmaWatch en 2026-08-10T16:00:40.000Z Helus Pharma to Participate at the Canaccord Genuity 46th Annual Growth Conference in Boston https://www.biopharmawatch.com/news/NTHI/neonc-phase-2a-data-readout-anticipation BiopharmaWatch en 2026-08-10T14:53:36.756Z NeOnc Heads into a High-Stakes Week as Highly Anticipated NEO100 Phase 2a Data Readout Nears https://www.biopharmawatch.com/news/ONC/beone-revolution-medicines-collaboration-oncology BiopharmaWatch en 2026-08-10T14:01:00.000Z Riassunto: BeOne Medicines e Revolution Medicines annunciano una collaborazione per lo sviluppo clinico e la commercializzazione regionale https://www.biopharmawatch.com/news/CON/concentra-investor-conferences-2026 BiopharmaWatch en 2026-08-10T13:30:00.000Z Concentra to Present at Upcoming Investor Conferences https://www.biopharmawatch.com/news/GOSS/kuehn-law-investigates-gossamer-bio BiopharmaWatch en 2026-08-10T13:24:00.000Z Kuehn Law Encourages Investors of Gossamer Bio, Inc. to Contact Law Firm https://www.biopharmawatch.com/news/BMRN/biomarin-participate-canaccord-growth-conference-2026 BiopharmaWatch en 2026-08-10T13:05:00.000Z BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-appoints-david-polinsky-board BiopharmaWatch en 2026-08-10T13:01:00.000Z Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-manufacturing-investment-houston BiopharmaWatch en 2026-08-10T13:01:00.000Z Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas https://www.biopharmawatch.com/news/NTHI/neonc-reports-q2-2026-results-and-phase-2a-data-readout BiopharmaWatch en 2026-08-10T13:00:31.000Z NeOnc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a NEO100 Data Readout https://www.biopharmawatch.com/news/NXTC/xcellon-biologics-acquires-nextcure-gmp-facility BiopharmaWatch en 2026-08-10T13:00:00.000Z Xcellon Biologics Acquires GMP Manufacturing Facility from NextCure, Becoming an End-to-End CRDMO for Next-Generation Bioconjugates and Complex Biologics https://www.biopharmawatch.com/news/ADUS/addus-homecare-leadership-change-bickham-dixon BiopharmaWatch en 2026-08-10T13:00:00.000Z Addus HomeCare Announces Departure of Heather Dixon and Return of Brad Bickham as Chief Operating Officer on an Interim Basis https://www.biopharmawatch.com/news/IBRX/immunitybio-appoints-dr-jim-yong-kim-vice-chairman BiopharmaWatch en 2026-08-10T13:00:00.000Z ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman https://www.biopharmawatch.com/news/ARTL/artelo-phase-2-trial-art27-13-glaucoma BiopharmaWatch en 2026-08-10T12:47:00.000Z Artelo Announces Enrollment of First Patient in a Phase 2 Clinical Trial Evaluating ART27.13 for Treatment of Glaucoma https://www.biopharmawatch.com/news/KURA/kura-oncology-ziftomenib-publication-blood BiopharmaWatch en 2026-08-10T12:46:04.185Z Kura Oncology Announces Publication in Blood Highlighting Ziftomenib’s Differentiated Binding Profile and Preclinical Activity https://www.biopharmawatch.com/news/COGT/cogent-biosciences-reports-q2-2026-results BiopharmaWatch en 2026-08-10T12:45:25.758Z Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/SILO/silo-pharma-european-patent-ptsd-therapy BiopharmaWatch en 2026-08-10T12:44:12.821Z Silo Pharma Granted European Patent Covering Novel PTSD Therapy https://www.biopharmawatch.com/news/AIM/aim-immunotech-reports-q2-2026-results-and-phase-3-plans BiopharmaWatch en 2026-08-10T12:36:00.000Z AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3 Development in Pancreatic Cancer https://www.biopharmawatch.com/news/NTHI/neonc-technologies-investor-call-phase-2a-results BiopharmaWatch en 2026-08-10T12:30:11.000Z NeOnc Technologies to Host Investor Conference Call to Discuss Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma https://www.biopharmawatch.com/news/ASBP/aspire-biopharma-acquires-dura-driver-control-systems BiopharmaWatch en 2026-08-10T12:30:00.000Z Aspire Biopharma Completes Acquisition of Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue https://www.biopharmawatch.com/news/BDMD/baird-medical-alpmed-partnership-advancing-ire-technology BiopharmaWatch en 2026-08-10T12:30:00.000Z Baird Medical and Alpmed Enter Strategic Partnership to Advance Irreversible Electroporation (IRE) Technology Globally https://www.biopharmawatch.com/news/WVE/wave-life-sciences-redomiciliation-delaware BiopharmaWatch en 2026-08-10T12:30:00.000Z Wave Life Sciences Announces Completion of Redomiciliation to Delaware https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-08-10T12:30:00.000Z Capricor Therapeutics to Report Second Quarter 2026 Financial Results and Provide Recent Corporate Update on August 13 https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-q2-2026-results-update BiopharmaWatch en 2026-08-10T12:30:00.000Z Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/EHC/encompass-health-private-offering-senior-notes-2034 BiopharmaWatch en 2026-08-10T12:28:00.000Z Encompass Health announces launch of private offering of 5.875% senior notes due 2034 https://www.biopharmawatch.com/news/AMIX/autonomix-medical-dr-robert-schwartz-award BiopharmaWatch en 2026-08-10T12:20:00.000Z Autonomix Medical Congratulates Co-Founder & Chief Medical Officer Dr. Robert Schwartz on Receiving Prestigious 2026 Cardiovascular Tech Forum Lifetime Achievement Award https://www.biopharmawatch.com/news/DCGO/docgo-second-quarter-2026-results-announcement BiopharmaWatch en 2026-08-10T12:16:00.000Z DocGo to Announce Second Quarter 2026 Results on Monday, August 17, 2026 https://www.biopharmawatch.com/news/ACXP/acurx-partnership-leiden-university-antibiotics BiopharmaWatch en 2026-08-10T12:01:00.000Z Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics https://www.biopharmawatch.com/news/QTRX/quanterix-appoints-jim-gute-cfo BiopharmaWatch en 2026-08-10T12:01:00.000Z Quanterix Names Jim Gute Chief Commercial Officer https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-launches-spy772-phase-2-trial BiopharmaWatch en 2026-08-10T12:00:24.000Z Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-10T12:00:23.000Z Heron Therapeutics Announces Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/RANI/rani-therapeutics-canaccord-genuity-conference BiopharmaWatch en 2026-08-10T12:00:12.000Z Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/TELO/telomir-zinc-suppresses-tumor-growth-tnbc-prostate-cancer BiopharmaWatch en 2026-08-10T12:00:00.000Z Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models https://www.biopharmawatch.com/news/NVO/novo-nordisk-aws-partnership-accelerate-drug-discovery BiopharmaWatch en 2026-08-10T12:00:00.000Z Novo Nordisk and AWS enter strategic partnership to accelerate drug discovery through AI https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-phase-1-study-eli-002-7p BiopharmaWatch en 2026-08-10T12:00:00.000Z Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma https://www.biopharmawatch.com/news/ALVO/alvotech-financial-results-h1-2026 BiopharmaWatch en 2026-08-10T12:00:00.000Z Alvotech to Report Financial Results for H1 2026 https://www.biopharmawatch.com/news/REPL/replimune-announces-pricing-150-million-offering BiopharmaWatch en 2026-08-10T12:00:00.000Z Replimune Announces Pricing of $150 Million Underwritten Offering https://www.biopharmawatch.com/news/QTRX/quanterix-financial-results-q2-2026 BiopharmaWatch en 2026-08-10T12:00:00.000Z Quanterix Releases Financial Results for the Second Quarter of 2026 https://www.biopharmawatch.com/news/RVTY/revvity-launches-superflex-prenatal-screening-system BiopharmaWatch en 2026-08-10T12:00:00.000Z Revvity Launches SuperFlex Prenatal Screening System, Expanding Access to Preeclampsia Testing https://www.biopharmawatch.com/news/OMER/omeros-corporation-q2-2026-financial-results-announcement BiopharmaWatch en 2026-08-10T12:00:00.000Z Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026 https://www.biopharmawatch.com/news/BSX/boston-scientific-wells-fargo-conference-2026 BiopharmaWatch en 2026-08-10T12:00:00.000Z Boston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 results https://www.biopharmawatch.com/news/CRVO/cervomed-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-10T11:57:32.052Z CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates https://www.biopharmawatch.com/news/EIKN/eikon-therapeutics-appoints-johnny-bennett-scientific-advisory-board BiopharmaWatch en 2026-08-10T11:30:00.000Z Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board https://www.biopharmawatch.com/news/GLAS/glass-house-brands-q2-2026-earnings-call BiopharmaWatch en 2026-08-10T11:30:00.000Z Glass House Brands to Host Second Quarter 2026 Earnings Call on August 13, 2026 https://www.biopharmawatch.com/news/SGRY/surgery-partners-q2-2026-results-guidance BiopharmaWatch en 2026-08-10T11:30:00.000Z Surgery Partners, Inc. Announces Second Quarter 2026 Results Reaffirms Full Year 2026 Guidance https://www.biopharmawatch.com/news/SLN/silence-therapeutics-phase-2-sanreco-trial-results BiopharmaWatch en 2026-08-10T11:30:00.000Z Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile https://www.biopharmawatch.com/news/SNDA/sonida-senior-living-q2-2026-results BiopharmaWatch en 2026-08-10T11:30:00.000Z Sonida Senior Living Announces Second Quarter 2026 Results https://www.biopharmawatch.com/news/KPTI/karyopharm-report-q2-2026-financial-results BiopharmaWatch en 2026-08-10T11:30:00.000Z Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026 https://www.biopharmawatch.com/news/CBLL/ceribell-fda-clearance-eeg-ai-enhancements BiopharmaWatch en 2026-08-10T11:23:09.866Z Ceribell Receives FDA Clearance for Advanced Epileptiform Abnormality Detection and Artifact Reduction for Its Cloud-Based Portal, Delivering Greater Precision for Critical-Care EEG Review https://www.biopharmawatch.com/news/SLN/silence-therapeutics-q2-2026-results BiopharmaWatch en 2026-08-10T11:15:00.000Z Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-q2-2026-results BiopharmaWatch en 2026-08-10T11:14:36.051Z Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights https://www.biopharmawatch.com/news/MLTX/moonlake-phase-3-izar-1-trial-sonelokimab-results BiopharmaWatch en 2026-08-10T11:13:44.305Z MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TENX/tenax-phase-3-level-trial-results BiopharmaWatch en 2026-08-10T11:05:00.000Z Orion’s license partner Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not reach its primary endpoint https://www.biopharmawatch.com/news/ACB/aurora-cannabis-2026-agm-results BiopharmaWatch en 2026-08-10T11:04:00.000Z Aurora, a Global Leader in Medical Cannabis, Announces Results of 2026 Annual General Meeting https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-08-10T11:03:00.000Z Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/APGE/abbvie-acquires-apogee-13511-per-share BiopharmaWatch en 2026-08-10T11:00:28.000Z Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates https://www.biopharmawatch.com/news/NXTC/avere-therapeutics-500-million-private-placement-avr-001 BiopharmaWatch en 2026-08-10T11:00:00.000Z Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001 https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-10T11:00:00.000Z Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/BRKR/bruker-majority-investment-mimetas-drug-discovery BiopharmaWatch en 2026-08-10T11:00:00.000Z Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-anaphylm-study-results BiopharmaWatch en 2026-08-10T11:00:00.000Z Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film https://www.biopharmawatch.com/news/SION/sionna-therapeutics-cystic-fibrosis-update BiopharmaWatch en 2026-08-10T11:00:00.000Z Sionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update https://www.biopharmawatch.com/news/JBIO/jade-biosciences-q2-2026-financial-results-update BiopharmaWatch en 2026-08-10T11:00:00.000Z Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/GRFS/grifols-sparta-phase-3-trial-completion BiopharmaWatch en 2026-08-10T11:00:00.000Z Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-phase-3-level-trial-results BiopharmaWatch en 2026-08-10T11:00:00.000Z Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF https://www.biopharmawatch.com/news/LH/labcorp-fda-approval-companion-diagnostic-melanoma BiopharmaWatch en 2026-08-10T11:00:00.000Z Labcorp Announces FDA Approval of Companion Diagnostic Supporting Patients with Advanced Melanoma https://www.biopharmawatch.com/news/SI/shoulder-innovations-promotes-jon-osborne-cco BiopharmaWatch en 2026-08-10T11:00:00.000Z Shoulder Innovations Promotes Jon Osborne to Chief Commercial Officer https://www.biopharmawatch.com/news/ACH/accendra-health-tax-asset-preservation-plan BiopharmaWatch en 2026-08-10T10:50:00.000Z Accendra Health Announces Adoption of Tax Asset Preservation Plan To Protect Long Term Shareholder Value https://www.biopharmawatch.com/news/ACH/accendra-health-q2-2026-financial-results BiopharmaWatch en 2026-08-10T10:45:00.000Z Accendra Health Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/SCNI/scinai-appoints-eran-kuratz-supply-chain-leader BiopharmaWatch en 2026-08-10T10:34:00.000Z Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration https://www.biopharmawatch.com/news/VERU/veru-fiscal-2026-q3-results-phase-2b-trial-update BiopharmaWatch en 2026-08-10T10:30:00.000Z Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress https://www.biopharmawatch.com/news/ACH/accendra-health-ceo-retirement-announcement BiopharmaWatch en 2026-08-10T10:30:00.000Z Accendra Health’s Ed Pesicka Announces Intent to Retire; Board of Directors Has Begun Successor Search https://www.biopharmawatch.com/news/RVMD/revolution-medicines-beone-collaboration BiopharmaWatch en 2026-08-10T10:01:00.000Z Revolution Medicines and BeOne Medicines Announce Clinical Development and Regional Commercialization Collaboration https://www.biopharmawatch.com/news/ONC/beone-revolution-collaboration-oncology-development BiopharmaWatch en 2026-08-10T10:00:00.000Z BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-lock-up-extension-2027 BiopharmaWatch en 2026-08-10T10:00:00.000Z Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027 https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-08-10 BiopharmaWatch en 2026-08-10T07:15:32.710Z Biotech Catalysts to Watch: Key Developments for August 2026 https://www.biopharmawatch.com/news/OCS/oculis-acquires-privosegtor-from-accure-therapeutics BiopharmaWatch en 2026-08-10T07:01:00.000Z Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company https://www.biopharmawatch.com/news/CDRE/seegene-global-screening-approach-gmcs BiopharmaWatch en 2026-08-10T07:00:00.000Z Seegene propose une approche globale de dépistage des infections de l'appareil génital dans le cadre de la Global Million Clinical Study (GMCS) https://www.biopharmawatch.com/news/IPHA/sobi-innate-partnership-lacutamab-t-cell-lymphoma BiopharmaWatch en 2026-08-10T06:32:00.000Z Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma https://www.biopharmawatch.com/news/IPHA/innate-pharma-lacutamab-phase-3-partnership-sobi BiopharmaWatch en 2026-08-10T06:30:00.000Z Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer https://www.biopharmawatch.com/news/IPHA/innate-pharma-partnership-sobi-lacutamab-ctcl BiopharmaWatch en 2026-08-10T06:00:00.000Z Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma https://www.biopharmawatch.com/news/CMMB/online-gambling-digital-payments-bonuses BiopharmaWatch en 2026-08-10T02:24:30.000Z Ovocný Zen 1Win – CZ Start Winning https://www.biopharmawatch.com/news/CMMB/online-casinos-technology-security-promotions BiopharmaWatch en 2026-08-10T02:24:28.000Z Bezplatné Online Kasino Bez Vkladu F1 . národní území Get Bonus Now https://www.biopharmawatch.com/news/JAZZ/jazz-acquires-actio-biosciences-epilepsy-portfolio BiopharmaWatch en 2026-08-10T00:00:00.000Z Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Actio Biosciences, Inc. (Actio Biosciences) today announced the companies have entered into a definitive... https://www.biopharmawatch.com/news/CMMB/online-gambling-casino-platform-analysis BiopharmaWatch en 2026-08-09T22:40:01.000Z Slammer Și Bandit Cu O Singură Mână Înapoi Betmen Bet — RO Unlock Offer